Candida albicans and other pathogenic vaginal fungi

Candida albicans and other pathogenic vaginal fungi, such as C. glabrata and C. tropicalis, are the primary causative agents of vulvovaginal candidiasis (VVC) [StatPearls, 2023]. These organisms are eukaryotic microorganisms rather than single molecular targets; however, they contain specific enzymes and structural components that serve as targets for antifungal therapy [CDC, 2021]. The most prominent molecular target within these fungi is lanosterol 14-alpha-demethylase (ERG11), which is essential for ergosterol biosynthesis and is inhibited by azole antifungals [PubMed, PMC3708393]. Another critical target is 1,3-beta-D-glucan synthase, an enzyme responsible for cell wall integrity that is targeted by echinocandins and triterpenoids [PubMed, PMC2897062]. Pathogenic Candida species can transition from commensal yeast to invasive hyphal forms, a process regulated by various signaling pathways that are also areas of therapeutic interest [Nature Reviews Microbiology, 2017]. Clinical management is complicated by the emergence of antifungal resistance, particularly in non-albicans species, necessitating the development of novel agents like oteseconazole which targets fungal-specific CYP51 [FDA, 2022]. Overall, these fungi represent a complex biological challenge where drug efficacy depends on penetrating biofilms and overcoming diverse resistance mechanisms [Journal of Fungi, 2020]. Understanding the specific species involved is critical, as non-albicans species frequently exhibit higher levels of resistance to standard azole therapies [Journal of Fungi, 2020].

Other names

Vaginal yeastVulvovaginal candidiasis pathogensCandida speciesVVC pathogens

Drugs targeting these fungi typically act by inhibiting lanosterol 14-alpha-demethylase to deplete ergosterol (azoles), inhibiting 1,3-beta-D-glucan synthase to disrupt the cell wall (echinocandins/triterpenoids), or binding directly to ergosterol to create membrane pores (polyenes) [PubMed, PMC4804516].